Phase II study of 90Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. Issue 6 (June 2015)

• Record Type: Journal Article
• Authors: Lossos, Izidore S.; Fabregas, Jesus C.; Koru-Sengul, Tulay; Miao, Feng; Goodman, Deborah; Serafini, Aldo N.; Hosein, Peter J.; Stefanovic, Alexandra; Rosenblatt, Joseph D.; Hoffman, James E.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 6(2015:Jun.)
• Page Start: 1750
• Page End: 1755
• Publication Date: 2015-06
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.975801
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>The best upfront therapy for patients with non-gastric extranodal marginal zone lymphomas (MZLs) is not defined. We assessed the safety and efficacy of radioimmunotherapy with ⁹⁰yttrium (⁹⁰Y) ibritumomab tiuxetan as upfront therapy in MZL (NCT00453102). A total of 16 patients were enrolled, 81% with advanced-stage disease and 44% with bulky disease. The overall response rate (ORR) at 12 weeks post-therapy was 87.5% (90% confidence interval [CI]: 65.6–97.7%), including a complete response in eight (50%), complete response unconfirmed in one (6%) and partial response in five (31%) patients. With a median follow-up of 65.6 months (range 4.0–96.5), the median progression-free survival (PFS) was 47.6 months (range 4.0–93.3) and median overall survival (OS) was not reached. The 5-year PFS was 40% (90% CI: 19.9–59.5%) and 5-year OS was 71.8% (90% CI: 46.8–86.5%). Overall, ⁹⁰Y ibritumomab tiuxetan was well tolerated and led to long-term responses and PFS rates.</p> </abstract>